ExoCoBio published Research Paper on ‘The World’s First Exosome-Based Treatment for Atopic Dermatitis’
ExoCoBio Inc., based in South Korea, published a scientific paper on that stem cell-derived exosomes dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets in the journal of Stem Cell Research and Therapy.
According to the paper, the symptoms of mice having severe atopic dermatitis were significantly improved after administration of stem cell-derived exosomes intravenously or subcutaneously, so that the level of serum immunoglobulin E (IgE), the number of eosinophils in blood, and the number of mast cells in the skin lesion were decreased. It has also been found that the number of inflammatory dendritic epidermal cells (IDECs), which are not found in normal skin but cause an allergic inflammatory response in atopic dermatitis lesions, also significantly decreased to a normal skin level after administration of stem cell-derived exosomes. In addition, the improvement of the symptoms by stem cell-derived exosomes was comparable to that of a steroid drug, Prednisolone.
Source: PRweb 2018. 8.24
LINK